Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome
NCT00765557 is a phase early 1 interventional trial sponsored by University of Texas Southwestern Medical Center. As of 18 Nov 2026, it is completed. It studies MiraLAX and Placebo in Constipation. The registry lists an enrollment of 138 participants. The registry lists a start date of 10 Dec 2007 and a primary completion date of 17 Jun 2014.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00765557 |
| Status | Completed |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | University of Texas Southwestern Medical Center |
| Enrollment | 138 |
| Conditions | Constipation |
| Drugs | MiraLAX and Placebo |
| Start | 10 Dec 2007 |
| Primary completion | 17 Jun 2014 |
| Study completion | 22 Jul 2014 |
| Last update posted | 15 Jan 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Warren T Snodgrass, MD
PARC Urology
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00765557
Each answer restates registry values shown on this page.
What is NCT00765557?
NCT00765557 is a phase early 1 interventional trial sponsored by University of Texas Southwestern Medical Center. It studies MiraLAX and Placebo in Constipation.
Who leads NCT00765557?
The registry names Warren T Snodgrass, MD (principal investigator, PARC Urology) as the overall official.
Which drugs does NCT00765557 study?
The registered drug and biological interventions are MiraLAX and Placebo.
When did NCT00765557 end?
The registry lists a primary completion date of 17 Jun 2014 and a study completion date of 22 Jul 2014. The sponsor last updated the record on 15 Jan 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.